Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7019066 | 0.90 | NPSR1 (0.56) | NPSR1MAPTHPGDRECQLALDH1A1 | |
| SCHEMBL21708066 | 0.85 | NPSR1 (0.43) | NPSR1MAPTHPGDRECQLALDH1A1 | |
| SCHEMBL10998213 | 0.85 | MAPT (0.46) | MAPTHPGDRECQLALDH1A1GAA | |
| SCHEMBL11579997 | 0.82 | MAPT (0.44) | MAPTHPGDRECQLALDH1A1GAA | |
| SCHEMBL11578876 | 0.82 | MAPT (0.49) | MAPTHPGDRECQLALDH1A1GAA | |
| SCHEMBL7480184 | 0.82 | GABRP (0.45) | MAPTHPGDRECQLALDH1A1GAA | |
| SCHEMBL6663907 | 0.80 | HPGD (0.43) | NPSR1MAPTHPGDRECQLALDH1A1 | |
| SCHEMBL9045800 | 0.80 | NPSR1 (0.46) | NPSR1MAPTHPGDRECQLALDH1A1 | |
| SCHEMBL9044351 | 0.80 | NPSR1 (0.46) | NPSR1MAPTHPGDALDH1A1GAA | |
| SCHEMBL6368861 | 0.77 | ALDH1A1 (0.47) | MAPTHPGDRECQLALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110787-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110787-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | RPL35, ZC3HAV1, RPL5 | NPSR1 3548/4885MAPT 2999/4885HPGD 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.